{
    "hands_on_practices": [
        {
            "introduction": "The shift towards evidence-based medicine in the mid-20th century was cemented by the adoption of the Randomized Controlled Trial (RCT) as the gold standard for proving a drug's efficacy. Before a single patient is enrolled, however, a critical question must be answered: how many participants are needed? This exercise  walks you through the fundamental statistical principles used to determine the necessary sample size, ensuring a trial has enough power to detect a real effect without wasting resources or unethically exposing too many participants.",
            "id": "4777240",
            "problem": "As randomized controlled trials (RCTs) became the evidentiary backbone of drug evaluation during the mid-twentieth-century rise of the pharmaceutical industry, firms increasingly needed to plan trial sizes from first principles of statistical inference rather than ad hoc convention. Consider a planned superiority RCT with equal allocation between $2$ arms testing a new small-molecule antihypertensive agent against standard care, where the primary endpoint is a continuous change score (baseline to follow-up) in systolic blood pressure. Assume independent observations, approximate normality of the endpoint within each arm, a common population standard deviation $\\sigma$, and a targeted mean difference (new minus control) equal to $\\delta$ under the alternative hypothesis.\n\nStarting from the definitions of Type I error $\\alpha$ and power $1-\\beta$ for a two-sided test of equality of means and the large-sample normal approximation to the sampling distribution of the difference in sample means, derive an analytic expression for the required equal per-arm sample size $n$ that would detect a true mean difference of magnitude $\\delta$ with two-sided significance level $\\alpha$ and power $1-\\beta$, assuming known common standard deviation $\\sigma$ and using a $z$-based test.\n\nThen, for the specific planning parameters $\\delta = 5$, $\\sigma = 10$, $\\alpha = 0.05$, and power $= 0.8$ (so $\\beta = 0.2$), evaluate the derived expression numerically to obtain the real-valued output of the sample size formula before any integer rounding rules typically applied in practice. Round your final numerical result to $4$ significant figures and report the value as a pure number with no units.",
            "solution": "The problem requires the derivation of a formula for the per-arm sample size, $n$, in a two-arm randomized controlled trial (RCT) with equal allocation. This derivation will be based on specified statistical parameters for a two-sided $z$-test of the difference between two means. Subsequently, the formula will be evaluated for a given set of numerical parameters.\n\nLet $\\mu_T$ be the population mean change in systolic blood pressure for the new agent arm and $\\mu_C$ be the population mean change for the standard care (control) arm. The objective of the superiority trial is to test whether the new agent produces a different mean change than the standard care. The null and alternative hypotheses for a two-sided test are:\n$$H_0: \\mu_T = \\mu_C \\quad (\\text{or } \\mu_T - \\mu_C = 0)$$\n$$H_1: \\mu_T \\neq \\mu_C \\quad (\\text{or } \\mu_T - \\mu_C \\neq 0)$$\n\nLet $\\bar{X}_T$ and $\\bar{X}_C$ be the sample mean changes in the treatment and control arms, respectively, each based on a sample of size $n$. The estimator for the difference in population means is $\\bar{D} = \\bar{X}_T - \\bar{X}_C$. Given that the observations are independent and normally distributed with a common standard deviation $\\sigma$, the sampling distribution of $\\bar{D}$ is also normal.\n\nThe expected value of $\\bar{D}$ is $E[\\bar{D}] = E[\\bar{X}_T] - E[\\bar{X}_C] = \\mu_T - \\mu_C$.\nThe variance of $\\bar{D}$ is $Var(\\bar{D}) = Var(\\bar{X}_T) + Var(\\bar{X}_C) = \\frac{\\sigma^2}{n} + \\frac{\\sigma^2}{n} = \\frac{2\\sigma^2}{n}$.\nThe standard error of the difference is $SE(\\bar{D}) = \\sqrt{\\frac{2\\sigma^2}{n}} = \\sigma \\sqrt{\\frac{2}{n}}$.\n\nUnder the null hypothesis $H_0$, where $\\mu_T - \\mu_C = 0$, the test statistic $Z$ is given by:\n$$Z = \\frac{\\bar{D} - 0}{SE(\\bar{D})} = \\frac{\\bar{X}_T - \\bar{X}_C}{\\sigma \\sqrt{2/n}}$$\nThis statistic follows a standard normal distribution, $Z \\sim N(0, 1)$.\n\nThe Type I error rate, $\\alpha$, is the probability of rejecting $H_0$ when it is true. For a two-sided test, we reject $H_0$ if the absolute value of the test statistic exceeds a critical value. Let $z_{\\gamma}$ denote the upper critical value of the standard normal distribution such that $P(Z > z_{\\gamma}) = \\gamma$. The rejection region is thus defined by $|Z| > z_{\\alpha/2}$. This is equivalent to rejecting $H_0$ if $\\bar{D} > z_{\\alpha/2} \\sigma \\sqrt{2/n}$ or $\\bar{D} < -z_{\\alpha/2} \\sigma \\sqrt{2/n}$.\n\nPower, $1-\\beta$, is the probability of correctly rejecting $H_0$ when the alternative hypothesis $H_1$ is true. We assume a specific alternative hypothesis where the true mean difference is $\\mu_T - \\mu_C = \\delta$. Under this alternative, the sampling distribution of $\\bar{D}$ is $N(\\delta, 2\\sigma^2/n)$.\n\nThe power is the probability that $\\bar{D}$ falls into the rejection region, calculated under this alternative distribution:\n$$1 - \\beta = P(\\bar{D} > z_{\\alpha/2} \\sigma \\sqrt{2/n} \\ | \\ \\mu_T - \\mu_C = \\delta) + P(\\bar{D} < -z_{\\alpha/2} \\sigma \\sqrt{2/n} \\ | \\ \\mu_T - \\mu_C = \\delta)$$\nTo evaluate these probabilities, we standardize $\\bar{D}$ using its distribution under $H_1$:\n$$1 - \\beta = P\\left( \\frac{\\bar{D} - \\delta}{\\sigma \\sqrt{2/n}} > \\frac{z_{\\alpha/2} \\sigma \\sqrt{2/n} - \\delta}{\\sigma \\sqrt{2/n}} \\right) + P\\left( \\frac{\\bar{D} - \\delta}{\\sigma \\sqrt{2/n}} < \\frac{-z_{\\alpha/2} \\sigma \\sqrt{2/n} - \\delta}{\\sigma \\sqrt{2/n}} \\right)$$\nThe standardized variable $\\frac{\\bar{D} - \\delta}{\\sigma \\sqrt{2/n}}$ is a standard normal variable, $Z'$.\n$$1 - \\beta = P\\left( Z' > z_{\\alpha/2} - \\frac{\\delta}{\\sigma \\sqrt{2/n}} \\right) + P\\left( Z' < -z_{\\alpha/2} - \\frac{\\delta}{\\sigma \\sqrt{2/n}} \\right)$$\nAssuming the effect size $\\delta$ is positive, for a reasonably powered study, the term $-z_{\\alpha/2} - \\frac{\\delta}{\\sigma \\sqrt{2/n}}$ becomes a large negative number, and the probability $P(Z' < \\dots)$ becomes negligible. Therefore, we can approximate the power by the first term:\n$$1 - \\beta \\approx P\\left( Z' > z_{\\alpha/2} - \\frac{\\delta\\sqrt{n}}{\\sigma\\sqrt{2}} \\right)$$\nBy definition of power, we also know that $1 - \\beta = P(Z' > -z_{\\beta})$, where $z_\\beta$ is the upper $\\beta$ critical value. Equating the arguments of the probability functions, we get:\n$$-z_{\\beta} = z_{\\alpha/2} - \\frac{\\delta\\sqrt{n}}{\\sigma\\sqrt{2}}$$\nRearranging this equation to solve for $n$:\n$$z_{\\alpha/2} + z_{\\beta} = \\frac{\\delta\\sqrt{n}}{\\sigma\\sqrt{2}}$$\n$$\\sqrt{n} = \\frac{(z_{\\alpha/2} + z_{\\beta}) \\sigma \\sqrt{2}}{\\delta}$$\nSquaring both sides yields the final analytic expression for the per-arm sample size $n$:\n$$n = \\frac{2\\sigma^2(z_{\\alpha/2} + z_{\\beta})^2}{\\delta^2}$$\n\nNow, we evaluate this expression for the specific parameters provided:\n-   Mean difference to detect, $\\delta = 5$.\n-   Common standard deviation, $\\sigma = 10$.\n-   Two-sided significance level, $\\alpha = 0.05$.\n-   Power, $1-\\beta = 0.8$, which implies a Type II error rate of $\\beta = 0.2$.\n\nWe need the corresponding critical values from the standard normal distribution:\n1.  For $\\alpha = 0.05$, we need $z_{\\alpha/2} = z_{0.025}$. This is the value for which the upper tail probability is $0.025$, corresponding to a cumulative probability of $1 - 0.025 = 0.975$. The value is $z_{0.025} \\approx 1.959964$.\n2.  For $\\beta = 0.2$, we need $z_{\\beta} = z_{0.2}$. This is the value for which the upper tail probability is $0.2$, corresponding to a cumulative probability of $1 - 0.2 = 0.8$. The value is $z_{0.2} \\approx 0.841621$.\n\nSubstituting these values into the derived formula for $n$:\n$$n = \\frac{2(10)^2(1.959964 + 0.841621)^2}{5^2}$$\n$$n = \\frac{2(100)(2.801585)^2}{25}$$\n$$n = \\frac{200}{25} \\times (2.801585)^2$$\n$$n = 8 \\times 7.848879...$$\n$$n = 62.79103...$$\n\nThe problem requires rounding the final numerical result to $4$ significant figures. The first four significant digits are $6, 2, 7, 9$. The fifth digit is $1$, so we round down.\n$$n \\approx 62.79$$",
            "answer": "$$\\boxed{62.79}$$"
        },
        {
            "introduction": "Once a drug's efficacy is established, the focus shifts to its practical application, namely, determining the correct dosage. The rise of pharmacokinetics provided a scientific framework for this by modeling how drug concentrations change over time in the body. This practice  invites you to work with a foundational one-compartment model, using a differential equation to predict a drug's plasma concentration and assess whether it remains within its effective therapeutic range.",
            "id": "4777227",
            "problem": "In the mid-twentieth century, the rise of large-scale pharmaceutical manufacturers led to systematic standardization of dosing and therapeutic monitoring. A central innovation was the adoption of one-compartment, first-order elimination models to describe plasma drug concentrations, which supported rational dose scheduling and helped formalize therapeutic thresholds such as the Minimal Inhibitory Concentration (MIC). Consider a historically representative scenario in which a single intravenous bolus dose of an early antibiotic yields an initial plasma concentration $C_0=20\\,\\mathrm{mg/L}$. Empirical pharmacokinetic studies of the era demonstrated that, for many drugs, elimination could be modeled by the first-order differential equation\n$$\\frac{dC(t)}{dt}=-k_{el}\\,C(t),$$\nwhere $C(t)$ is the plasma concentration at time $t$ and $k_{el}$ is the first-order elimination rate constant. Suppose $k_{el}=0.2\\,\\mathrm{h}^{-1}$ for this antibiotic, and the MIC-derived therapeutic threshold is $5\\,\\mathrm{mg/L}$. Starting from the differential equation and the initial condition $C(0)=C_0$, derive the concentration function $C(t)$ and compute $C(4\\,\\mathrm{h})$. In your reasoning, assess whether the concentration at $t=4\\,\\mathrm{h}$ remains above the therapeutic threshold of $5\\,\\mathrm{mg/L}$. Express the final concentration in $\\mathrm{mg/L}$ and round your numerical answer to four significant figures. Provide the numerical value of $C(4\\,\\mathrm{h})$ as your final answer.",
            "solution": "The problem requires the derivation of a plasma drug concentration function, its evaluation at a specific time, and a comparison with a therapeutic threshold. The process begins with the validation of the problem statement.\n\n**Problem Validation**\n\n**Step 1: Extracted Givens**\n- Initial plasma concentration: $C_0=20\\,\\mathrm{mg/L}$\n- Governing differential equation: $\\frac{dC(t)}{dt}=-k_{el}\\,C(t)$\n- First-order elimination rate constant: $k_{el}=0.2\\,\\mathrm{h}^{-1}$\n- Therapeutic threshold (Minimal Inhibitory Concentration, MIC): $5\\,\\mathrm{mg/L}$\n- Initial condition: $C(0)=C_0$\n- Time of interest: $t=4\\,\\mathrm{h}$\n\n**Step 2: Validation Using Extracted Givens**\nThe problem is scientifically grounded. It presents a standard one-compartment, first-order elimination model, which is a fundamental and widely used concept in pharmacokinetics. The provided differential equation is a classic representation of this model. The values for the initial concentration ($C_0$), the elimination rate constant ($k_{el}$), and the therapeutic threshold are all physically realistic and dimensionally consistent. The problem is well-posed, constituting a standard initial value problem with a unique and stable solution. The language is objective and precise. Therefore, the problem is valid.\n\n**Step 3: Verdict and Action**\nThe problem is deemed valid and a formal solution will be derived.\n\n**Solution Derivation**\n\nThe model for the plasma concentration $C(t)$ is described by the first-order linear ordinary differential equation:\n$$\n\\frac{dC(t)}{dt}=-k_{el}\\,C(t)\n$$\nThis equation is separable. We can rearrange it to separate the variables $C$ and $t$:\n$$\n\\frac{1}{C(t)} dC(t) = -k_{el}\\,dt\n$$\nTo find the specific solution that satisfies the initial condition $C(0)=C_0$, we integrate both sides. The left side is integrated from the initial concentration $C_0$ to the concentration $C(t)$ at a later time $t$. The right side is integrated from the initial time $t=0$ to the time $t$.\n$$\n\\int_{C(0)}^{C(t)} \\frac{1}{C'} dC' = \\int_{0}^{t} -k_{el}\\,dt'\n$$\nPerforming the integration yields:\n$$\n[\\ln|C'|]_{C_0}^{C(t)} = [-k_{el}t']_{0}^{t}\n$$\nSince plasma concentration must be a non-negative physical quantity, we can drop the absolute value operator.\n$$\n\\ln(C(t)) - \\ln(C_0) = -k_{el}t - (-k_{el} \\cdot 0)\n$$\nUsing the properties of logarithms, we combine the terms on the left side:\n$$\n\\ln\\left(\\frac{C(t)}{C_0}\\right) = -k_{el}t\n$$\nTo solve for $C(t)$, we exponentiate both sides of the equation with base $e$:\n$$\n\\exp\\left(\\ln\\left(\\frac{C(t)}{C_0}\\right)\\right) = \\exp(-k_{el}t)\n$$\n$$\n\\frac{C(t)}{C_0} = \\exp(-k_{el}t)\n$$\nThis gives the explicit function for concentration over time:\n$$\nC(t) = C_0 \\exp(-k_{el}t)\n$$\nThis is the derived concentration function $C(t)$.\n\nNow, we compute the concentration at $t=4\\,\\mathrm{h}$ using the given values: $C_0 = 20\\,\\mathrm{mg/L}$ and $k_{el} = 0.2\\,\\mathrm{h}^{-1}$.\n$$\nC(4\\,\\mathrm{h}) = 20 \\times \\exp(-0.2 \\times 4)\n$$\n$$\nC(4\\,\\mathrm{h}) = 20 \\times \\exp(-0.8)\n$$\nWe calculate the numerical value:\n$$\n\\exp(-0.8) \\approx 0.44932896\n$$\n$$\nC(4\\,\\mathrm{h}) \\approx 20 \\times 0.44932896 = 8.9865792\\,\\mathrm{mg/L}\n$$\nThe problem requires rounding the final numerical answer to four significant figures.\n$$\nC(4\\,\\mathrm{h}) \\approx 8.987\\,\\mathrm{mg/L}\n$$\nFinally, we assess whether this concentration is above the therapeutic threshold of $5\\,\\mathrm{mg/L}$.\n$$\n8.987\\,\\mathrm{mg/L} > 5\\,\\mathrm{mg/L}\n$$\nThe concentration at $t=4\\,\\mathrm{h}$ remains above the therapeutic threshold. The final answer is the numerical value of $C(4\\,\\mathrm{h})$ rounded to four significant figures.",
            "answer": "$$\n\\boxed{8.987}\n$$"
        },
        {
            "introduction": "A drug's story does not end with its approval; in many ways, it's just beginning. As a drug is used by a larger and more diverse population, rare side effects may emerge, demanding a continuous evaluation of its risk-benefit profile. This problem  introduces you to two powerful tools from clinical epidemiology, the Number Needed to Treat (NNT) and the Number Needed to Harm (NNH), allowing you to quantify and directly compare the clinical benefit of a drug against its potential dangers.",
            "id": "4777210",
            "problem": "A mid-20th-century randomized controlled trial conducted during the rapid expansion of the pharmaceutical industry evaluated a new oral agent introduced to reduce post-myocardial infarction mortality. Investigators reported that, over a two-year horizon in trial populations typical of that era, the drug’s Number Needed to Treat (NNT), defined in clinical epidemiology as the number of patients who must receive the treatment for one additional beneficial outcome to occur compared with control, was $12$. Subsequent pharmacovigilance, a practice that matured as the industry grew and regulatory standards tightened, identified a rare serious adverse event whose absolute risk increase was measured as $0.002$ relative to control over the same horizon in the same population. Using first principles of absolute risk and expected value, compute the expected Number Needed to Harm (NNH), defined as the number of patients who must receive the treatment for one additional harmful outcome to occur compared with control. Then, from a history-of-medicine perspective grounded in the rise of the pharmaceutical industry, explain how the computed NNH compares to the reported NNT and what that implies for risk–benefit decision-making in that era’s evolving regulatory context. Express your final NNH as an integer count of patients; no rounding instruction is required beyond reporting the integer implied by the calculation. Do not include any units in your final numeric answer.",
            "solution": "The problem statement will first be validated against the required criteria.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n- Trial Context: A mid-20th-century randomized controlled trial for a new oral agent to reduce post-myocardial infarction mortality.\n- Time Horizon: Two-year.\n- Number Needed to Treat (NNT): $12$.\n- Definition of NNT: The number of patients who must receive the treatment for one additional beneficial outcome to occur compared with control.\n- Adverse Event: A rare serious adverse event identified through subsequent pharmacovigilance.\n- Absolute Risk Increase (ARI) of the adverse event: $0.002$ relative to control over the same horizon in the same population.\n- Definition of Number Needed to Harm (NNH): The number of patients who must receive the treatment for one additional harmful outcome to occur compared with control.\n- Required Computations and Analysis:\n    1. Compute the expected NNH.\n    2. Explain how the computed NNH compares to the reported NNT from a history-of-medicine perspective, focusing on risk–benefit decision-making in the context of the rise of the pharmaceutical industry.\n- Final Answer Format: NNH expressed as an integer.\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientific and Factual Soundness:** The problem is grounded in core principles of clinical epidemiology and pharmacology. The definitions of NNT, NNH, and Absolute Risk Increase are standard. The historical context—the rise of the pharmaceutical industry, the establishment of randomized controlled trials, and the later maturation of pharmacovigilance in the mid-20th century—is factually accurate. The numerical values provided ($NNT=12$, $ARI=0.002$) are plausible within this context. The problem does not violate any scientific principles or contain factual errors.\n- **Well-Posed and Self-Contained:** The problem is well-posed. It provides all necessary information to calculate the NNH. The definition of NNH directly relates to the provided ARI. The question is clear and leads to a unique numerical solution for the NNH and a well-defined conceptual analysis.\n- **Objectivity:** The problem is stated in objective, formal language, free of bias or subjective claims.\n\n**Step 3: Verdict and Action**\nThe problem is valid. It is scientifically sound, well-posed, and objective. A complete solution will be provided.\n\n### Solution\n\nThe first step is to compute the Number Needed to Harm (NNH) using the principles of risk assessment. The Number Needed to Harm is defined as the number of patients who must be treated for one additional harmful outcome to occur, compared to a control group. This is mathematically the reciprocal of the Absolute Risk Increase (ARI) for the harm.\n\nLet $P_T(\\text{harm})$ be the probability (absolute risk) of the adverse event in the treatment group and $P_C(\\text{harm})$ be the probability of the adverse event in the control group. The Absolute Risk Increase is defined as:\n$$ARI_{\\text{harm}} = P_T(\\text{harm}) - P_C(\\text{harm})$$\nThe problem states that the absolute risk increase for the rare serious adverse event is $0.002$.\n$$ARI_{\\text{harm}} = 0.002$$\nThe Number Needed to Harm ($NNH$) is the inverse of the $ARI_{\\text{harm}}$:\n$$NNH = \\frac{1}{ARI_{\\text{harm}}}$$\nSubstituting the given value for $ARI_{\\text{harm}}$:\n$$NNH = \\frac{1}{0.002} = \\frac{1}{2 \\times 10^{-3}} = \\frac{1000}{2} = 500$$\nThus, the expected Number Needed to Harm is $500$. This means that for every $500$ patients treated with the new oral agent for two years, one additional serious adverse event is expected to occur that would not have occurred otherwise.\n\nThe second part of the task is to compare this computed $NNH$ of $500$ with the given Number Needed to Treat ($NNT$) of $12$ from a history-of-medicine perspective, specifically in the context of the mid-20th-century pharmaceutical industry and its regulatory environment.\n\nThe $NNT = 12$ indicates that treating $12$ patients for two years prevents one death from post-myocardial infarction. This represents a substantial therapeutic benefit. The risk-benefit profile is therefore characterized by these two numbers:\n- **Benefit (NNT):** $12$ patients treated to save $1$ life.\n- **Harm (NNH):** $500$ patients treated to cause $1$ serious adverse event.\n\nTo make a direct comparison, one can consider the outcomes per a fixed number of patients, for instance, $500$. In a group of $500$ patients treated for two years, one would expect:\n- Number of lives saved: $\\frac{500}{NNT} = \\frac{500}{12} \\approx 41.67$\n- Number of serious adverse events caused: $\\frac{500}{NNH} = \\frac{500}{500} = 1$\n\nFrom a mid-20th-century perspective, this risk-benefit ratio would have been considered exceptionally favorable. During this era of rapid pharmaceutical expansion, the primary focus of drug development and regulation was on demonstrating efficacy, especially for life-threatening conditions like myocardial infarction, which had high mortality and few effective treatments. The establishment of the randomized controlled trial as the gold standard was itself a major development, and a finding as dramatic as an $NNT$ of $12$ would have been hailed as a breakthrough.\n\nSimultaneously, the science and practice of pharmacovigilance—the systematic monitoring of drug safety after a product is on the market—were nascent. Before the strengthening of regulatory bodies like the FDA (e.g., via the $1962$ Kefauver-Harris Amendments in the U.S., spurred by the thalidomide tragedy), the capacity to detect, quantify, and act upon rare adverse events was limited. The discovery of a harm with an $ARI$ of $0.002$ ($1$ in $500$) represents a level of post-marketing surveillance that was only beginning to mature as the industry grew.\n\nTherefore, for a physician, regulator, or pharmaceutical company in that period, the decision-making calculus would be clear: a drug that saves approximately $42$ lives for every $1$ serious adverse event it causes offers a profound net benefit to public health. The high mortality of the underlying disease would make the risk of a rare side effect seem acceptable, if not negligible. This problem neatly encapsulates a key theme in the history of the pharmaceutical industry: the initial, powerful drive for potent new therapies was gradually balanced by an evolving, more sophisticated system for understanding and managing the inevitable risks associated with them, a regulatory and scientific maturation that continues to this day.",
            "answer": "$$\\boxed{500}$$"
        }
    ]
}